157 related articles for article (PubMed ID: 19012510)
1. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer.
Chi KN; Zoubeidi A; Gleave ME
Expert Opin Investig Drugs; 2008 Dec; 17(12):1955-62. PubMed ID: 19012510
[TBL] [Abstract][Full Text] [Related]
2. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.
Zielinski R; Chi KN
Future Oncol; 2012 Oct; 8(10):1239-51. PubMed ID: 23130925
[TBL] [Abstract][Full Text] [Related]
3. Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma.
Xiu P; Dong XF; Li XP; Li J
World J Gastroenterol; 2015 Jul; 21(27):8262-70. PubMed ID: 26217078
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.
Chi KN; Siu LL; Hirte H; Hotte SJ; Knox J; Kollmansberger C; Gleave M; Guns E; Powers J; Walsh W; Tu D; Eisenhauer E
Clin Cancer Res; 2008 Feb; 14(3):833-9. PubMed ID: 18245546
[TBL] [Abstract][Full Text] [Related]
5. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.
Chi KN; Eisenhauer E; Fazli L; Jones EC; Goldenberg SL; Powers J; Tu D; Gleave ME
J Natl Cancer Inst; 2005 Sep; 97(17):1287-96. PubMed ID: 16145049
[TBL] [Abstract][Full Text] [Related]
6. Potential use of custirsen to treat prostate cancer.
Higano CS
Onco Targets Ther; 2013; 6():785-97. PubMed ID: 23836992
[TBL] [Abstract][Full Text] [Related]
7. Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer.
Al-Asaaed S; Winquist E
Curr Oncol Rep; 2013 Apr; 15(2):113-8. PubMed ID: 23266703
[TBL] [Abstract][Full Text] [Related]
8. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
9. Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen.
Blumenstein B; Saad F; Hotte S; Chi KN; Eigl B; Gleave M; Jacobs C
Cancer Med; 2013 Aug; 2(4):468-77. PubMed ID: 24156019
[TBL] [Abstract][Full Text] [Related]
10. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.
So A; Sinnemann S; Huntsman D; Fazli L; Gleave M
Mol Cancer Ther; 2005 Dec; 4(12):1837-49. PubMed ID: 16373699
[TBL] [Abstract][Full Text] [Related]
12. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.
Zoubeidi A; Chi K; Gleave M
Clin Cancer Res; 2010 Feb; 16(4):1088-93. PubMed ID: 20145158
[TBL] [Abstract][Full Text] [Related]
13. Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapy.
Praharaj PP; Patra S; Panigrahi DP; Patra SK; Bhutia SK
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188500. PubMed ID: 33385484
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer.
Zhang X; Liu C; Li K; Wang K; Zhang Q; Cui Y
Medicine (Baltimore); 2019 Feb; 98(6):e14254. PubMed ID: 30732140
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Saad F; Hotte S; North S; Eigl B; Chi K; Czaykowski P; Wood L; Pollak M; Berry S; Lattouf JB; Mukherjee SD; Gleave M; Winquist E;
Clin Cancer Res; 2011 Sep; 17(17):5765-73. PubMed ID: 21788353
[TBL] [Abstract][Full Text] [Related]
16. The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target.
Muhammad LA; Saad F
Expert Rev Anticancer Ther; 2015; 15(9):1049-61. PubMed ID: 26313417
[TBL] [Abstract][Full Text] [Related]
17. Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
Schmitz G
Curr Opin Mol Ther; 2006 Dec; 8(6):547-54. PubMed ID: 17243491
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
[TBL] [Abstract][Full Text] [Related]
19. A population pharmacokinetic meta-analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects.
Edwards AY; Elgart A; Farrell C; Barnett-Griness O; Rabinovich-Guilatt L; Spiegelstein O
Br J Clin Pharmacol; 2017 Sep; 83(9):1932-1943. PubMed ID: 28294391
[TBL] [Abstract][Full Text] [Related]
20. Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model.
Nishikawa M; Miyake H; Gleave M; Fujisawa M
Target Oncol; 2017 Feb; 12(1):69-79. PubMed ID: 27526062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
